Smart Immune Announces the Launch of its T Cell Progenitor-based Platform of Next-Generation Biotherapies for Severe Infections and Leukemia

PARIS, January 22, 2020 – 2.00 PM CET - Smart Immune today announced the launch of its proprietary platform of T cell progenitor-based biotherapies intended for the treatment of severe infections and leukemia. Following a successful seed fundraising round of € 2.8 million completed with a € 1.88million grant of the French BPI Q4 2019, the Smart Immune team is advancing its lead cell therapy program T cell progenitors or ProTcells TM (CD7+/CD34- ; CD5- cells) which is currently being studied in three clinical trials, the first of which is currently recruiting children suffering from severe combined immunodeficiency (SCID) at Necker Children’s Hospital in Paris. Early evidence for the treatment’s safety and
efficacy is expected by the beginning of 2021.